TITLE

Sipuleucel-T

AUTHOR(S)
Higano, Celestia S.; Small, Eric J.; Schellhammer, Paul; Yasothan, Uma; Gubernick, Steven; Kirkpatrick, Peter; Kantoff, Philip W.
PUB. DATE
July 2010
SOURCE
Nature Reviews Drug Discovery;Jul2010, Vol. 9 Issue 7, p513
SOURCE TYPE
Academic Journal
DOC. TYPE
journal article
ABSTRACT
In April 2010, sipuleucel-T (Provenge; Dendreon), an autologous cellular immunotherapy, was approved by the US FDA for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. It is the first therapeutic cancer vaccine to receive FDA approval.
ACCESSION #
51882774

 

Related Articles

  • FDA approves Dendreon's prostate cancer trial protocol.  // PharmaWatch: Cancer;July 2003, Vol. 2 Issue 7, p29 

    Announces United States Food and Drug Administration's (FDA) notification of biotechnology firm, Dendreon, that a late-stage round of testing involving its prostate-cancer vaccine Provenge will serve as the basis for a biologics license application. Collaboration of Dendreon with the FDA to...

  • Immunotherapy data may signal new era in advanced PCa care. Kerr, Richard R. // Urology Times;6/1/2009, Vol. 37 Issue 7, p6 

    The article reports on the study of sipuleucel-T agent as an experimental form of immonutherapy for androgen-independent prostate cancer in Chicago, Illinois. Accordingly, the agent could change the paradigm for treating the cancer if approved by the Food and Drug Administration (FDA). In...

  • Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Sharma, Padmanee; Wagner, Klaus; Wolchok, Jedd D.; Allison, James P. // Nature Reviews Cancer;Nov2011, Vol. 11 Issue 11, p805 

    The US Food and Drug Administration (FDA) recently approved two novel immunotherapy agents, sipuleucel-T and ipilimumab, which showed a survival benefit for patients with metastatic prostate cancer and melanoma, respectively. The mechanisms by which these agents provideclinical benefit are not...

  • Cellular immunotherapy licensed for advanced prostate cancer. Traynor, Kate // American Journal of Health-System Pharmacy;6/1/2010, Vol. 67 Issue 11, p862 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved the used of cellular immunotherapy in the treatment of prostate cancer. It mentions that FDA approved the use of sipuleucel- T, or Provenge, for the treatment of prostate cancer that is resistant to standard...

  • Provenge: The Saga Continues. Silverman, Ed // Contract Pharma;Sep2010, Vol. 12 Issue 7, p46 

    The article focuses on the controversy of the Provenge prostate cancer vaccine as a stimulant to a patient's own immune system to target cancer cells in the U.S. The vaccine was recommended by the Food and Drug Administration (FDA) in May 2007 which later triggered debate about the agency's...

  • Landmark approval for Dendreon's cancer vaccine. DeFrancesco, Laura // Nature Biotechnology;Jun2010, Vol. 28 Issue 6, p531 

    The article focuses on the approval by the U.S. Food and Drug Administration (FDA) of the Provenge prostate cancer vaccine from Dendreon on April 29, 2010. Such approval may be viewed as a success for the study of cancer immunotherapy. Various groups of individuals believe in the value of...

  • Multidisciplinary Care for CRPC. Sartor, A. Oliver // AUANews;Sep2014, Vol. 19 Issue 9, p1 

    The article discusses multidisciplinary care for castration resistant prostate cancer (CRPC). Topics covered include how the history of hormonal treatment in prostate care started with the work of Dr. Charles Huggins, the use of many forms of hormonal therapy, immunotherapy, chemotherapy, and...

  • Targeting the hypoxia-adenosinergic signaling pathway to improve the adoptive immunotherapy of cancer. Sitkovsky, Michail; Ohta, Akio // Journal of Molecular Medicine;Feb2013, Vol. 91 Issue 2, p147 

    The recent approval by the FDA of cancer vaccines and drugs that blockade immunological negative regulators has further enhanced interest in promising approaches of the immunotherapy of cancer. However, the disappointingly short life extension has also underscored the need to better understand...

  • Designer lymphocytes to fight cancer: a helping hand from modern molecular biology. Kiessling, Rolf // Journal of Molecular Medicine;Nov2010, Vol. 88 Issue 11, p1081 

    The article focuses on cancer vaccines and their development. It says that vaccines for cancer are based on activating the patients' adaptive immune response to eliminate tumor cells. It states that Dendreon Corp.'s Sipuleucel-T or Provenge cancer vaccine was the first vaccine approved by U.S....

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics